Does the shingles vaccine Zostavax reverse the skin-specific T cell defect to varicella zoster challenge?

Trial Profile

Does the shingles vaccine Zostavax reverse the skin-specific T cell defect to varicella zoster challenge?

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Feb 2016 Accrual to date is 41% according to United Kingdom Clinical Research Network.
    • 11 Feb 2016 Planned End Date changed from 10 Oct 2017 to 31 Jan 2017, according to United Kingdom Clinical Research Network.
    • 27 Nov 2015 Planned End Date changed from 10 Oct 2015 to 10 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top